Therapeutic Tumor Infiltrating Lymphocytes
Information
- Drug Name
- Therapeutic Tumor Infiltrating Lymphocytes
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer |
KRAS p.Gly12Asp (p.G12D) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D) ( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 27959684 | Detail |
| colorectal cancer | HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY | C |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 27959684 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A patient with metastatic colorectal cancer was en... | KRAS |
KRAS p.Gly12Asp (p.G12D) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D) ( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| A patient with metastatic colorectal cancer was en... | HLA-C | HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02500576 | Completed | Phase 2 | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | August 7, 2015 | October 12, 2022 |
| NCT00002572 | Completed | Phase 1 | Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors | November 1994 | December 1999 |
| NCT00002733 | Completed | Phase 2 | Biological Therapy in Treating Patients With Metastatic Cancer | January 1996 | January 2000 |
| NCT00002786 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Metastatic Melanoma | October 1995 | March 2006 |
| NCT00003665 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | April 1999 | November 2002 |
| NCT00002535 | Completed | Phase 2 | Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | July 1993 | July 2004 |
| NCT00019084 | Completed | Phase 2 | Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | February 1996 | May 2003 |
| NCT00019357 | Completed | Phase 1 | Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | June 1998 | |
| NCT00045149 | Completed | Phase 1 | Biological Therapy in Treating Patients With Metastatic Melanoma | October 2002 | June 2005 |
| NCT00046852 | Completed | Phase 1/Phase 2 | Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma | December 2001 | February 2008 |
| NCT00062036 | Completed | Phase 1/Phase 2 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | June 2003 | September 2008 |
| NCT00085462 | Completed | Phase 1 | Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | May 2004 | September 2008 |
| NCT00091104 | Completed | Phase 1 | Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | July 2004 | October 2010 |
| NCT00096382 | Completed | Phase 2 | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | September 2004 | January 2009 |
| NCT00301730 | Completed | Phase 1 | Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung | October 2005 | |
| NCT01807182 | Completed | Phase 2 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | August 20, 2013 | August 26, 2021 |
| NCT00006113 | Terminated | Phase 2 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | June 1999 | April 2006 |